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ao the Editor: “. . .but did not reduce the rate of cardiovascular
vents. . .” were the concluding words in the abstract of the
ecently published NAVIGATOR (Nateglinide and Valsartan in
mpaired Glucose Tolerance Outcomes Research) study (1), which
ssessed the effects of valsartan on the incidence of diabetes and
ardiovascular events in more than 9,000 patients. Although blood
ressure (BP) was significantly lower by 2.8/1.4 mm Hg in the
alsartan arm when compared with placebo and the risk of diabetes
as lessened, disappointingly the coprimary cardiovascular outcomes
composite of death from cardiovascular cause, nonfatal myocardial
nfarction, nonfatal stroke, hospitalization for heart failure, arterial
evascularization, and hospitalization for unstable angina) were similar
etween the groups. Similar to NAVIGATOR, the National Heart,
ung and Blood Institute–sponsored ACCORD (Action to Control
ardiovascular Risk in Diabetes) study (2) in 4,733 patients with type
diabetes showed that targeting systolic BP to 120 mm Hg as
ompared with140 mm Hg “did not reduce the rate of a composite
utcome of fatal and non-fatal major cardiovascular events.” And,
nally, we should remember that in the DREAM (Diabetes Reduc-
ion Assessment With Ramipril and Rosiglitazone Medication) study
3), in more than 5,000 patients with impaired fasting glucose levels
r impaired glucose tolerance, “the use of ramipril for 3 years did
ot significantly reduce the incidence of diabetes or death. . .” nor
id ramipril “reduce the risk of the cardiorenal composite out-
ome.” Not uncommonly, the concluding line of the abstract of a
andmark study becomes the one and only line that sticks in the
racticing clinician’s mind. Thus, the nihilistic conclusions from
he 3 major recent studies in patients with diabetes or impaired
asting glycemia are that aggressive lowering of BP to systolic goals
elow 140 mm Hg (achieved BP of 133, 128, and 119 mm Hg in
AVIGATOR, DREAM, and ACCORD, respectively) confers
o benefits whatsoever. This certainly is a disturbing finding given
ur teaching over more than 2 decades, ever since Syst-Eur
Systolic Hypertension in Europe) (4) and HOT (Hypertension
ptimal Treatment) (5) trials, that diabetes renders patients
articularly susceptible to the effects of BP lowering and that
ndeed a given fall in BP conferred distinctly more benefits in the
atient with diabetes than in the patient without. In Syst-Eur (6),
or instance, active treatment reduced all cardiovascular events by
9% in patients with diabetes as opposed to only 26% in patients
ithout diabetes (4). Not surprisingly, most, if not all, recent
ypertension guidelines adopted significantly lower BP goals for
he patient with diabetes than for the hypertensive patient without
iabetes. Obviously, these unexpected findings in 3 major recent
rials are prone to have a major impact on the state of the art of
ntihypertensive therapy in patients with impaired glucose toler-
nce or type 2 diabetes. However, because stroke is the most
P-dependent cardiovascular outcome, we decided to scrutinize
N
nhe 3 recent landmark studies for cerebrovascular events. The
esults from 19,309 patients with diabetes or impaired fasting
lucose suggest that intensive BP control is associated with a
8% reduction in the risk of stroke (odds ratio: 0.72; 95%
onfidence interval: 0.28 to 0.89) when compared with routine
ontrol (Fig. 1). Treatment of 174 patients with aggressive BP
ontrol for 4.8 years will prevent 1 stroke.
High BP certainly remains a powerful risk factor for coronary
eart disease and for congestive heart failure. However, many
tudies have shown that BP reduction confers distinctly more
enefit for prevention of strokes than for prevention of heart
isease (7,8). The reason for this discrepancy is not entirely clear,
lthough it may be related to the extensive use of thiazide diuretics
n many studies. Evidence has been put forward that thiazides are
articularly efficacious for stroke prevention (9) and mutatis
utandis particularly inefficacious for prevention of coronary artery
isease. This cerebroprotective effect, first observed by Brown and
rown (10), seems to be, at least to some extent, independent of
he thiazides’ BP-lowering effect and may be related to stimulation
f the AT2 receptor (9). Regardless of the exact mechanism for
troke reduction (and the lack of coronary artery disease reduction)
n the 3 major landmark trials, these results deserve our attention.
t stands to reason that cardiologists are more concerned with
oronary artery disease than with cerebrovascular disease. How-
ver, stroke remains the most devastating complication of hyperten-
ive cardiovascular disease. Clearly, a 28% reduction of cerebrovascular
vents cannot be swept under the rug. As a post hoc finding in a
eta-analysis, it is by no means hypothesis testing but seems to
andate a thorough reinterpretation of the seemingly disappointing
esults in DREAM, ACCORD, and NAVIGATOR.
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nvestigations
s There a Kink in the Wire?
e read with interest the report by Tonino et al. (1) on behalf of
he FAME (Fractional Flow Reserve [FFR] Versus Angiography
n Multivessel Evaluation) investigators. They concluded that
angiography is inaccurate in assessing the functional significance
f a coronary stenosis when compared with the FFR, not only ineverity category” (1). The FAME study, including this more
etailed analysis, provides a strong foundation for moving toward
schemia-directed stent therapy in patients with symptomatic
oronary artery disease (2,3), and we agree with this in principle.
We are concerned, however, with the lack of clarity for how the
ercent diameter stenosis was determined in this study and
hether the conclusions are related to the fallibility of angiography
r the methods of angiographic analysis. Although it is valid to
onsider a visual estimate of angiographic severity for purposes of
he FAME trial, it should be clarified if this is the case before
onclusions regarding the value of angiography are made. It is welltrialsnown that visual estimates generally overestimate lesion severity
